Baekcho-ds
Licorice Ext
I World Pharmaceutical Co., Ltd.
Human Otc Drug
NDC 73442-0007Baekcho-ds also known as Licorice Ext is a human otc drug labeled by 'I World Pharmaceutical Co., Ltd.'. National Drug Code (NDC) number for Baekcho-ds is 73442-0007. This drug is available in dosage form of Syrup. The names of the active, medicinal ingredients in Baekcho-ds drug includes Licorice - 10 g/mL . The currest status of Baekcho-ds drug is Active.
Drug Information:
| Drug NDC: | 73442-0007 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Baekcho-ds |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Licorice Ext |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | I World Pharmaceutical Co., Ltd. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Syrup |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | LICORICE - 10 g/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 23 Mar, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 19 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | I World Pharmaceutical Co., Ltd.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 61ZBX54883
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 73442-0007-1 | 100 mL in 1 BOTTLE, GLASS (73442-0007-1) | 29 Mar, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
(loss of appetite), stomach bloating, dyspepsia, overeating, nausea, vomiting, suicide, constipation, dilute stools,
Product Elements:
Baekcho-ds licorice ext licorice licorice glycerin sucralose menthol
Indications and Usage:
Adult and 15 years and older: 1 time 10 ml pediatric patients were divided into two groups: 1 to 11 years old, 6.5 ml, 8 to 10 years old, 5.0 ml, 5 to 7 years old, 3.5 ml, 3-4 years old, 2.5 ml, take it three times a day after meals. the interval should be 4 hours or more.
Warnings:
1. do not take this medicine. do not take to infants (infants, babies) under 3 months. in addition, infants (infants and young babies) who are under the age of one for at least three months must give priority to receiving medical attention, and should not be taken unless they are inevitable. 2. consult a doctor, dentist or pharmacist before taking this medicine. 1) patients with hypertension, elderly (elderly), cardiac or renal (kidney) patients, edema (swelling) patients 2) people who are taking other medicines: potassium-containing preparations, licorice-containing preparations, glycyrrhizic acid or its salt-containing preparations, loop-type diuretics (furosemide, ethacrynic acid) or thiazide diuretics (trichloromethiazide) (combined with) aldosteronism or hypokalemia due to myocarditis (myopathy) is likely to occur due to taking it carefully. 3) patients receiving medical treatment 3. immediately stop taking this drug and consult a doctor, dentist or pharmacist if: have this attach
Read more...ed document at the time of consultation. 1) upper aldosteronism: if you have decreased urine volume, face and hands and feet are swollen, your eyelids are getting heavy, your hands are hardening, your blood pressure is getting high or you have a headache (such as a maximum dose of 1g per day as a licorice, observation (measurement of serum potassium levels) should be sufficient and should be discontinued if abnormality is confirmed, because gastric aldosteronism such as elevation of blood pressure, elevation of blood pressure, retention of sodium body fluid (swelling), swelling (swelling) 2) myopathy (myopathy): as a result of hypokalemia, myopathy (myopathy) may occur. if the observation is sufficient and anomalies such as helplessness, cramps and paralysis are confirmed 3) if there is no improvement in symptoms even for several days 4. other cautions when taking this medicine 1) keep the prescribed dosage and dosage. 2) when taking a child, take it under the supervision of a guardian. 3) do not take it for a long time. 5. storage precautions 1) keep out of reach of children. 2) taking medicines out of their original containers and storing them in other containers may cause accidents or poor quality of medicines due to misuse (misuse), so keep them in their original container and keep them tightly closed. 3) avoid direct sunlight and store in a cool, dry place.
Dosage and Administration:
For oral use only
Package Label Principal Display Panel:
Label